gl
via
drink
water
lead
increas
incid
preneoplast
lesion
socal
aberr
crypt
foci
colon
fischer
rat
well
appear
atherosclerot
lesion
aorta
anim
signific
differ
test
group
regard
format
lesion
colon
aorta
rat
observ
suggest
given
experiment
condit
lcarnitin
concentr
gl
drink
water
advers
effect
gastrointestin
vascular
system
fischer
rat
abstract
lcarnitin
key
compon
fatti
acid
oxid
nowaday
extens
use
nutrit
supplement
allegedli
fat
burn
performanceenhanc
properti
although
date
conclus
data
support
claim
furthermor
invers
relationship
exogen
supplement
bioavail
ie
fairli
high
oral
dose
fulli
absorb
thu
signific
amount
carnitin
remain
gut
human
rat
enterobacteria
degrad
unabsorb
lcarnitin
trimethylamin
trimethylaminenoxid
certain
condit
may
transform
known
carcinogen
nnitrosodimethylamin
recent
find
indic
trimethylaminenoxid
might
also
involv
develop
atherosclerot
lesion
therefor
investig
whether
administr
differ
lcarnitin
concentr
electron
supplementari
materi
onlin
version
articl
lcarnitin
key
compon
socal
carnitin
shuttl
multienzym
transport
system
requir
transfer
activ
longchain
fatti
acid
acylcoa
mitochondri
matrix
degrad
via
violant
et
al
cours
process
lcarnitin
conjug
acylcoa
carnitin
palmitoyltransferas
yield
acylcarnitin
transport
inner
mitochondri
compart
carnitin
acylcarnitin
translocas
cact
exchang
free
carnitin
houten
wander
thereaft
carnitin
palmitoyltransferas
retransform
acylcarnitin
acylcoa
ester
degrad
acylcoa
subunit
thu
gener
substrat
citric
acid
cycl
reduc
equival
electron
transport
chain
houten
wander
although
lcarnitin
present
plant
main
nutrit
sourc
human
foodstuff
anim
origin
mitchel
depend
dietari
habit
daili
intak
food
sourc
rang
mgkg
bodi
weight
bw
bioavail
gener
lower
human
regularli
consum
diet
high
lcarnitin
eg
abund
consumpt
red
meat
even
lower
high
amount
compound
supplement
exogen
harper
et
al
rebouch
sahajwalla
et
al
bodi
concentr
lcarnitin
tightli
regul
equilibrium
endogen
synthesi
lysin
methionin
renal
reabsorpt
dietari
lcarnitin
suppli
latter
especi
influenc
renal
clearanc
rate
evan
fornasini
jeukendrup
et
al
rebouch
therefor
oral
intraven
dosag
certain
basal
physiolog
threshold
level
lead
increas
lcarnitin
elimin
diminish
uptak
evan
fornasini
rebouch
seim
although
mechan
intestin
absorpt
lcarnitin
yet
fulli
elucid
like
involv
carriermedi
transport
well
passiv
diffus
latter
import
intak
rout
nondietari
ie
high
carnitin
concentr
evan
fornasini
li
et
al
activ
renal
reabsorpt
intestin
uptak
tissu
distribut
lcarnitin
mediat
socal
carnitineorgan
cation
transport
octn
two
identifi
human
tamai
rare
mutat
gene
encod
lead
system
carnitin
shortag
consequ
develop
primari
carnitin
defici
pcd
case
manifest
clinic
form
hypoketot
hypoglycem
encephalopathi
well
disord
heart
skelet
muscl
erguven
et
al
lahjouji
et
al
contrast
clinic
less
sever
secondari
carnitin
defici
scd
caus
organ
eg
kidney
liver
metabol
disord
eg
impair
fatti
acid
metabol
carnitin
malabsorpt
malnutrit
well
pharmacolog
treatment
erguven
et
al
flanagan
et
al
treatment
disord
especi
case
pcd
consist
daili
supplement
lcarnitin
dose
mgkg
bw
mg
timesday
adapt
patient
plasma
level
bain
et
al
longo
et
al
sinc
earli
lcarnitin
also
extens
advertis
use
athlet
bodybuild
even
obes
individu
nutrit
supplement
allegedli
fat
burn
performanceenhanc
properti
jeukendrup
et
al
although
date
conclus
data
support
claim
neither
rat
eder
melton
et
al
saldanha
aoki
et
al
human
barnett
et
al
brass
cerretelli
marconi
grunewald
bailey
jeukendrup
randel
jeukendrup
et
al
vukovich
et
al
take
account
invers
relationship
exogen
supplement
bioavail
one
must
conclud
fairli
high
oral
dose
given
signific
amount
lcarnitin
would
remain
gut
unabsorb
compound
partial
degrad
trimethylamin
tma
enterobacteria
gut
lumen
rat
greater
extent
human
koeth
et
al
rebouch
chenard
rebouch
et
al
zhang
et
al
absorpt
tma
oxid
trimethylaminenoxid
tmno
hepat
flavin
monooxygenas
baker
chaykin
bennett
et
al
koeth
et
al
addit
follow
lcarnitin
supplement
tmno
directli
produc
gut
gastrointestin
microbiota
koeth
et
al
acid
environ
presenc
nitrit
ion
ie
condit
prevail
upper
gastrointestin
tract
known
carcinogen
nnitrosodimethylamin
ndma
form
amin
precursor
bain
et
al
lijinski
et
al
loh
et
al
tricker
preussmann
addit
bacteri
metabol
also
lead
ndma
format
amin
tma
dimethylamin
maduagwu
bassir
consumpt
lcarnitin
dose
complet
absorb
might
thu
enhanc
bacteri
ndma
product
colon
consequ
contribut
colorect
tumor
format
shown
knekt
et
al
loh
et
al
dietari
ndma
therefor
investig
whether
chronic
administr
differ
lcarnitin
concentr
via
drink
water
lead
increas
number
aberr
crypt
foci
acf
consid
preneoplast
lesion
associ
colorect
cancer
format
bird
colon
male
fischer
rat
recent
studi
koeth
et
al
show
tmno
result
lcarnitin
supplement
promot
atherosclerosi
mice
addit
examin
influenc
occurr
atherosclerot
lesion
aorta
abovement
rat
eighti
male
fischer
ducrl
rat
rat
purchas
week
age
g
bw
charl
river
sulzfeld
germani
hous
type
iv
polycarbon
cage
ehret
emmendingen
germani
cage
place
airflow
cabinet
uni
protect
ehret
oper
posit
pressur
mode
pa
provid
temperatur
rel
humid
maximum
light
intens
lux
air
shift
per
hour
well
h
day
night
cycl
bed
consist
poplar
granul
lignocel
select
jr
rosenberg
germani
chang
week
diet
standard
pellet
rodent
mainten
diet
cat
nr
see
onlin
resourc
specif
anim
feed
detail
feed
composit
purchas
altromin
lage
germani
anim
cage
access
tunnel
hous
made
red
polycarbon
bioscap
castroprauxel
germani
certifi
carcinogen
toxicantfre
aspen
rod
abedd
lab
vet
servic
vienna
austria
enrich
experiment
design
procedur
upon
arriv
litterm
randomli
assign
one
four
test
group
consist
anim
hous
pairwis
cage
minim
distress
whole
experiment
period
week
anim
control
group
group
receiv
drink
tap
water
without
supplement
water
group
supplement
g
lcarnitinel
week
respect
lcarnitin
lonza
basel
switzerland
puriti
purchas
denk
ingredi
munich
germani
sialodacryoaden
viru
sdav
infect
see
result
lcarnitin
treatment
start
week
upon
arriv
acclimat
recoveri
period
week
avoid
microbi
contamin
drink
water
autoclav
carnitin
supplement
chang
twice
week
cours
water
chang
water
consumpt
record
weight
anim
assess
week
moreov
stabil
lcarnitin
water
assess
liquid
chromatographymass
spectrometri
lcm
period
day
experiment
condit
see
onlin
resourc
assess
lcarnitin
stabil
detail
administr
period
individu
rat
anaesthet
co
lmin
flush
decapit
blood
immedi
collect
analysi
gastrointestin
tract
entir
remov
process
previous
describ
nicken
et
al
briefli
colon
remov
wash
phosphat
buffer
salin
pb
open
longitudin
thereaft
tissu
fix
formalin
roti
histofix
carl
roth
karlsruh
germani
stain
methylen
blue
solut
wv
pb
acf
format
assess
use
stereomicroscop
olympu
hamburg
germani
addit
kidney
liver
spleen
remov
weigh
histopatholog
examin
heart
thorac
aorta
liver
fix
neutral
buffer
formalin
organ
trim
perform
accord
registri
industri
toxicolog
animaldata
rita
north
american
control
anim
databas
nacad
guidelin
organ
sampl
trim
rat
mice
morawietz
et
al
ruehlfehlert
et
al
follow
embed
paraffin
wax
section
thick
stain
hematoxylin
eosin
micrograph
repres
lesion
obtain
use
olympu
microscop
equip
megapixel
digit
color
camera
cellsen
standard
v
softwar
olympu
corp
tokyo
japan
figur
process
adob
photoshop
v
adob
system
inc
san
jose
ca
usa
therebi
adjust
contrast
bright
necessari
assess
ndma
concentr
urin
experiment
anim
urin
collect
nexttolast
week
studi
hous
anim
group
individu
metabol
cage
tecniplast
germani
h
gather
urin
sampl
ml
store
tube
greiner
bioon
frickenhausen
germani
protect
light
analysi
sampl
extract
perform
use
supelclean
coconut
charcoal
spe
tube
sigmaaldrich
schnelldorf
germani
base
us
environment
protect
agenc
method
detect
nitrosamin
drink
water
munch
bassett
ndma
restek
bad
homburg
germani
ad
urin
sampl
intern
standard
prior
sampl
prepar
nitrosamin
elut
spe
tube
use
methylen
chlorid
vwr
leuven
belgium
concentr
gentl
stream
nitrogen
volum
approxim
ml
aliquot
inject
gcm
residuefre
urin
avail
method
valid
perform
use
synthet
human
urin
synthet
urin
nussdorf
germani
spike
ndma
restek
sampl
analyz
agil
ga
chromatograph
waldbronn
germani
coupl
agil
mass
select
detector
msd
appli
follow
paramet
column
agil
dbwax
polyethylen
glycol
mm
id
film
thick
carrier
ga
helium
mlmin
constant
flow
oven
temperatur
program
min
min
backflush
min
program
temperatur
vapor
agil
multimod
inlet
inlet
temperatur
program
min
min
vent
flow
mlmin
bar
ioniz
ev
ei
sim
mode
mz
statist
analysi
data
perform
prism
v
graphpad
softwar
inc
la
jolla
ca
usa
shapirowilk
normal
test
use
assess
probabl
distribut
dataset
normal
distribut
set
subject
oneway
analysi
varianc
anova
follow
tukey
post
hoc
test
nonnorm
distribut
data
data
independ
experi
perform
shapirowilk
test
analysi
ndma
level
rat
urin
subject
kruskalw
test
follow
dunn
post
hoc
comparison
relationship
frequenc
pathohistolog
find
lcarnitin
treatment
analyz
mean
pearson
chisquar
test
statist
signific
consid
p
first
week
upon
arriv
anim
show
sign
sdav
infect
sdav
rel
common
ratspecif
coronaviru
high
morbid
lowtono
mortal
gaillard
clifford
jacobi
gaertner
infect
rel
silent
promin
clinic
symptom
sneez
follow
redcolor
nasal
discharg
group
one
anim
euthan
complet
studi
anim
complet
studi
good
gener
condit
statist
signific
differ
observ
group
regard
final
bodi
weight
anim
weigh
g
end
studi
tabl
final
bw
similarli
final
weight
variou
organ
sampl
differ
anim
differ
across
group
signific
manner
tabl
kidney
liver
spleen
weight
interestingli
rat
highest
dose
group
group
drank
significantli
water
anim
group
control
lowest
dose
tabl
water
uptak
base
averag
water
consumpt
ml
ratday
tabl
water
uptak
averag
bodi
weight
grat
tabl
regard
acf
format
acf
multipl
cryptsacf
statist
signific
differ
four
group
test
tabl
histopatholog
alter
aorta
seen
one
anim
control
group
show
mild
focal
degen
chang
media
accompani
mild
infiltr
macrophag
miner
fig
tabl
histopatholog
examin
heart
reveal
mild
multifoc
chronic
lymphohistiocyt
myocard
myocardi
degener
fibrosi
rat
statist
signific
differ
group
observ
fig
tabl
moreov
anim
display
variabl
degre
bile
duct
hyperplasia
fig
high
number
anim
show
mildtomoder
multifoc
acut
subacut
tabl
physiolog
data
experiment
anim
applic
valu
shown
mean
standard
deviat
weight
one
kidney
calcul
basi
mean
weekli
water
consumpt
two
animalscag
kruskalw
test
follow
dunn
post
hoc
analysi
b
oneway
anova
follow
tukey
post
hoc
analysi
significantli
differ
p
compar
group
significantli
differ
p
compar
group
group
gl
group
gl
group
gl
group
gl
number
anim
start
bodi
weight
g
final
bodi
weight
g
kidney
weight
g
liver
weight
g
b
spleen
weight
g
b
water
uptak
mldayanim
tabl
pathohistolog
find
aorta
heart
liver
anim
pathohistolog
find
analyz
pearson
chisquar
test
number
anim
mention
alterationtot
number
anim
analyz
frequenc
parenthes
group
gl
group
gl
group
gl
group
gl
fig
aorta
control
anim
mild
focal
degen
chang
media
accompani
mild
infiltr
macrophag
miner
arrowhead
l
lumen
b
heart
anim
group
mild
multifoc
chronic
lymphohistiocyt
myocard
myocardi
degener
fibrosi
c
liver
control
anim
mild
bile
duct
hyperplasia
associ
mild
lymphohistiocyt
infiltr
liver
control
anim
focal
suppur
necrot
hepat
scale
bar
b
scale
bar
c
suppur
necrot
hepat
fig
without
statist
signific
differ
group
tabl
except
hepatocellular
carcinoma
one
anim
group
tumor
observ
within
liver
remain
anim
signific
differ
regard
ndma
content
urin
anim
observ
test
group
fig
interestingli
anim
receiv
gl
lcarnitin
group
seem
excret
lowest
amount
ndma
median
concentr
reach
ngml
ngml
respect
group
ngml
group
ngml
howev
note
differ
statist
signific
amount
urinari
ndma
strongli
vari
anim
test
group
fig
final
mean
bodi
weight
rat
record
cours
studi
correspond
weight
measur
untreat
rat
age
solleveld
et
al
contrast
water
uptak
rat
studi
somewhat
reduc
compar
water
uptak
laboratori
rat
gener
hofstett
et
al
although
rat
administ
gl
lcarnitin
drank
significantli
water
anim
group
find
consid
biolog
irrelev
question
whether
actual
relat
lcarnitin
supplement
rat
extens
use
longterm
ie
yearslong
carcinogen
studi
dins
et
al
solleveld
et
al
character
extrem
low
spontan
incid
rate
neoplasm
small
larg
intestin
haseman
et
al
render
particularli
use
investig
put
colon
carcinogen
howev
acf
seem
spontan
develop
colon
rat
fairli
high
incid
even
anim
kill
earlier
age
present
studi
furukawa
et
al
tanakamaru
et
al
overal
frequenc
statist
signific
differ
number
acfsanim
test
group
acf
format
studi
consid
spontan
relat
lcarnitin
supplement
addit
data
obtain
cours
studi
show
administr
differ
lcarnitin
dosag
lead
increas
amount
ndma
excret
via
urin
compar
untreat
anim
fact
might
furthermor
explain
low
acf
incid
even
though
differ
test
group
note
basal
ndma
level
ngml
averag
nevertheless
observ
urin
anim
group
might
result
endogen
format
contamin
unknown
etiolog
kraft
et
al
tricker
preussmann
vermeer
et
al
regard
possibl
influenc
sdav
infect
outcom
studi
hand
mention
repair
process
affect
tissu
respiratori
tract
eye
salivari
lacrim
gland
begin
day
post
infect
case
salivari
lacrim
gland
complet
day
jacobi
gaertner
perci
et
al
sinc
sdav
infect
occur
begin
studi
anim
week
recov
suspect
major
effect
viru
outcom
studi
especi
sinc
sdav
known
interfer
colon
tumorigenesi
heartrel
patholog
jacobi
gaertner
latter
statement
well
fact
immunocompet
anim
develop
immun
recov
rel
fast
bare
sequela
jacobi
gaertner
led
decis
kill
entir
coloni
continu
experi
particularli
male
rat
develop
plethora
patholog
chang
increas
age
common
spontan
tumor
chronic
nephropathi
lesion
cardiovascular
system
coleman
et
al
king
russel
patholog
find
relat
cardiovascular
system
describ
studi
clearli
fall
categori
focal
myocardi
degener
conjunct
inflamm
lymphohistiocyt
infiltr
follow
myocardi
fibrosi
describ
age
rat
well
rat
strain
incid
compar
one
report
herein
especi
anim
fed
ad
libitum
blankenship
skagg
coleman
et
al
goodman
et
al
hall
et
al
keenan
et
al
b
maeda
et
al
context
left
ventricular
papillari
muscl
primarili
affect
fig
ndma
concentr
urin
experiment
anim
collect
nexttolast
week
studi
shown
median
well
ndma
level
individu
animalgroup
mean
three
measurementssampl
dataset
subject
kruskalw
test
follow
dunn
post
hoc
comparison
locat
numer
anim
data
shown
report
prefer
site
lesion
perci
barthold
addit
age
rat
commonli
exhibit
hyperplast
bile
duct
king
russel
accord
coleman
et
al
approxim
old
rat
show
bile
duct
hyperplasia
find
contrast
incid
report
studi
although
still
accord
sourc
similar
incid
report
significantli
older
anim
month
contrast
control
rat
use
carcinogen
studi
us
nation
institut
health
carcinogenesi
test
program
margin
suffer
bile
duct
hyperplasia
male
femal
rat
affect
goodman
et
al
frequenc
multifoc
suppur
necrot
liver
lesion
observ
studi
distinctli
rel
low
incid
spontan
necrot
process
previous
describ
age
male
rat
approx
hall
et
al
although
unabl
identifi
characterist
viral
bacteri
mycot
parasit
structur
within
liver
lesion
employ
routin
special
histolog
stain
method
gram
stain
period
acid
schiffreact
groccott
silver
stain
data
shown
rule
possibl
anim
infect
agent
clostridium
piliform
tyzzer
diseas
salmonella
spp
corynebacterium
kutscheri
perci
barthold
thoolen
et
al
howev
sinc
test
group
equal
affect
find
clearli
relat
lcarnitin
treatment
addit
consid
lesion
mainli
mild
subclin
grade
acut
charact
therefor
might
develop
last
day
last
week
studi
thu
render
influenc
acf
format
onset
cardiovascular
lesion
unlik
definit
sub
intim
atherosclerot
lesion
observ
aorta
anim
degen
chang
observ
aorta
one
control
rat
interpret
incident
find
unknown
etiolog
agreement
previous
report
rare
spontan
lesion
describ
old
rat
king
russel
sinc
find
concern
one
anim
control
group
carnitinerel
caus
exclud
addit
note
rat
except
special
bred
strain
gener
develop
atherosclerosi
king
russel
moghadasian
fact
togeth
differ
composit
gut
microbiota
metabol
lcarnitin
well
amount
gl
lcarnitin
given
apolipoprotein
eknockout
mice
might
explain
diverg
result
studi
hand
conduct
koeth
et
al
regard
format
atherosclerot
lesion
conclus
studi
provid
evid
daili
administr
lcarnitin
concentr
mgkg
bwday
year
lead
advers
effect
colon
cardiovascular
system
male
rat
